Oral Retinoids in the Treatment of Seborrhoea and Acne
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Isotretinoin is an extremely effective drug if given systemically in severe forms of seborrhoea and acne, being the only retinoid with potent sebostatic properties. Its unique activity on the sebaceous gland still remains unclear since isotretinoin barely binds to cellular retinoic-acid-binding proteins and to retinoic acid receptors. Its bioavailability is approximately 25% and can be increased by food 1.5–2 times; after 30 min, the drug is detectable in the blood and maximal concentrations are reached 2–4 h after oral intake. The major metabolites of isotretinoin in blood are 4-hydroxy- and 4-oxo-isotretinoin, while several glucuronides are detectable in the bile. 4-Oxo-isotretinoin is present in plasma in a 2- to 4-fold higher concentration 6 h after a single dose. Steady-state concentrations appear after 1 week. The half-life elimination rate of the parent compound ranges from 7 to 37 h while that of some metabolites does so from 11 to 50 h. Isotretinoin crosses the placenta and is recognized as a strong teratogenic compound. About 10–30% of the drug is metabolized via its isomer tretinoin. Excretion of isotretinoin occurs after conjugation with the faeces or after metabolization with the urine. The epidermal levels of isotretinoin are rather low and no progressive accumulation, either in serum or in the skin, is found. After discontinuation of therapy, isotretinoin disappears from serum and skin within 2–4 weeks. Isotretinoin is the most effective drug in reducing sebaceous gland size (up to 90%) by decreasing proliferation of basal sebocytes, suppressing sebum production and inhibiting sebocyte differentiation in vivo. The molecular basis for its antisebotrophic activity has not been fully elucidated. Isotretinoin also exhibits anti-inflammatory activities. Systemic isotretinoin is today the regimen of choice in severe seborrhoea, since it reduces sebocyte lipid synthesis by 75% with daily doses as low as 0.1 mg/kg after 4 weeks. Patients who have received oral isotretinoin therapy for seborrhoea do not usually experience a relapse for months or years. In severe acne, a 6- to 12-month treatment with isotretinoin 1 mg/kg/day reduced to 0.5 or 0.2 mg/kg/day according to the response is recommended (cumulative dose of >120 mg/kg). Contraception is essential during isotretinoin treatment in women of childbearing age 1 month before, during and for 3 months after discontinuation of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zouboulis, C. C., Korge, B., Akamatsu, H., Xia, L., Schiller, S., Gollnick, H., & Orfanos, C. E. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12471782 · Cited by 140
Self-citationKING, K., JONES, D. H., DALTREY, D. C., & CUNLIFFE, W. J. (1982) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1982.tb00410.x · Cited by 139
Epidemiology of isotretinoin exposure during pregnancy
Dai, W. S., LaBraico, J. M., & Stern, R. S. (1992) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(92)70088-w · Cited by 133 · cited 1×
“Considerable concern has been raised during the past decade requiring a better understanding of pharmacokinetics and the clinical relevance of circulating blood levels of isotretinoin [”
BackgroundAcne fulminans: report of clinical findings and treatment of twenty-four patients
Karvonen, S.-L. (1993) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(93)70076-6 · Cited by 103 · cited 1×
“Oestrogens, anti-androgens and their combinations inhibit sebum production by 12.5–65p. A combination of isotretinoin with systemic corticosteroids is initially required in acne fulminans. In contrast to the opinion that isotretinoin may be a frequent precipitating factor, in a series of 24 patients with acne fulminan…”
Influential
Cited by
Knop, E., Knop, N., Millar, T., Obata, H., & Sullivan, D. A. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6997c · Cited by 1,061
Acne and sebaceous gland function
Zouboulis, C. C. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.03.004 · Cited by 561
Self-citationCarazo, A., Macáková, K., Matoušová, K., Krčmová, L. K., Protti, M., & Mladěnka, P. (2021) · Nutrients · doi:10.3390/nu13051703 · Cited by 461
The Role of Vitamin A in Wound Healing
Polcz, M. E., & Barbul, A. (2019) · Nutrition in Clinical Practice · doi:10.1002/ncp.10376 · Cited by 205
Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review
Marqueling, A. L., & Zane, L. T. (2005) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2005.04.003 · Cited by 166
Metadata
- Authors
- Orfanos, C. E., & Zouboulis, C. C.
- Venue
- Dermatology
- Publisher
- S. Karger AG
- Published
- 1998
- Volume
- 196
- Issue
- 1
- Pages
- 140-147
- ISSN
- 1018-8665 (ISSN-L)
- 1421-9832
- OpenAlex
- W2128598938
- Cited by
- 129
- References
- 4
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Retinoids in the Treatment of Seborrhoea and Acne. https://app.cochat.ai/papers/10.1159/000017848
- The paper
- Orfanos, C. E., & Zouboulis, C. C. (1998). Oral Retinoids in the Treatment of Seborrhoea and Acne. Dermatology. https://doi.org/10.1159/000017848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.